The healthiest way to brew your coffee — and possibly lengthen your life – WDJT

By Sandee LaMotte, CNN

(CNN) -- For many of us, the day doesn't start off right until we have that cuppa joe.

Just the aroma of that dark, rich brew can get our senses stirring, ready for the mood boost we know is coming.

And it turns out that coffee's not just fine for your health, it may even lengthen your life -- but only if you prepare it with a filter, according to a new long-term study published Wednesday in the European Journal of Preventive Cardiology.

"Unfiltered coffee contains substances which increase blood cholesterol. Using a filter removes these and makes heart attacks and premature death less likely," said study author Dag Thelle, a senior professor in the public health and community medicine department of the University of Gothenburg, Sweden.

"Our study provides strong and convincing evidence of a link between coffee brewing methods, heart attacks and longevity," Thelle said.

That's bad news for lovers of coffee made with the French press, or cafetire, that is so popular today, or those fond of strong Greek and Turkish brewing methods. Boiling coffee or using a coffee press can actually increase your risk of heart disease.

"Unfiltered coffee, like Greek and Turkish coffee, which is boiled, or coffee made in a French press contain higher amounts of cafestol and kahweol -- chemicals found in oil droplets floating in the coffee and also in the sediment," said registered dietitian Lisa Drayer, a CNN health and nutrition contributor.

"Studies have shown that these substances can raise triglyceride levels and LDL cholesterol levels," Drayer said. "So stick with filtered coffee, such as a paper filter that you would use in a drip-brewed coffee, which can help to trap these chemicals."

The new study followed over half a million healthy Norwegian men and women between the ages of 20 and 79 over a 20-year period.

Results showed drinking boiled or pressed unfiltered coffee raised the risk of death in men aged 60 and above, due to elevated cardiovascular mortality.

But drinking filtered coffee -- that through a paper filter, for example, was found to be healthier than drinking no coffee at all.

Filtered coffee was linked to a 15% reduced risk of death from any cause, a 12% decreased risk of death from cardiovascular disease in men and a 20% lowered risk of death from heart disease in women when compared to drinking no coffee.

In fact, the study found those who drank one to four cups of filtered coffee per day had the lowest mortality rate.

"The finding that those drinking the filtered beverage did a little better than those not drinking coffee at all could not be explained by any other variable such as age, gender or lifestyle habits. So we think this observation is true," Thelle said.

The findings echo other research highlighting coffee's health benefits. According to the American Heart Association, filtered coffee can sharpen your mental focus, boost mood and improve performance during exercise.

The British Medical Journal published a huge umbrella study in 2017 that looked at over 200 meta-analyses of the health benefits of coffee and that found drinking three to fours cups of black coffee a day provides the most health benefits overall.

Those included lowering the risk of heart disease; numerous types of cancer; and neurological, metabolic and liver disorders; as well as overall mortality. Other studies have found coffee reduces the risk for melanoma, heart disease, multiple sclerosis, type 2 diabetes, liver disease, prostate cancer, Alzheimer's, computer-related back pain and more.

Of course, nothing is perfect. There are some reasons you may want to limit or avoid coffee.

Watch your sleep. "If you have trouble falling asleep, it's best to avoid coffee and all sources of caffeine in the evening or close to bedtime," Drayer suggested.

Careful if you're at risk for fractures. The British Medical Journal analysis found high levels of coffee consumption (over four cups a day) was associated with a higher risk of fractures in women who already had a greater likelihood, but not in men.

Pregnant women should also be wary. Higher levels of coffee consumption were found to increase risk for preterm births and stillbirths, as well as low birth weight in babies. This is possibly due to the fact that the half-life of caffeine is known to double during pregnancy, raising the dose of caffeine per cup, according to the study.

Not for those with Parkinson's. A study published in September 2017 reversed opinion on the benefits for Parkinson's disease, which was long thought to be helped by caffeine. Researchers who first found that coffee reduced tremors in those with Parkinson's went back and studied a larger sample of patients for a longer time. This time, they found no difference between those taking caffeine tablets and those taking a placebo. After the initial data came back negative, the study was stopped.

But for the vast majority of us, coffee is just fine, experts said.

"For people who know they have high cholesterol levels and want to do something about it, stay away from unfiltered brew, including coffee made with a cafetire," Thelle said. "For everyone else, drink your coffee with a clear conscience and go for filtered."

To keep your coffee consumption even more healthy, Drayer suggested the following tips:

Add low-fat milk and skip the cream. "Cream contributes about 50 calories and 3 grams of saturated fat per tablespoon," Drayer said, adding that low-fat milk has fewer calories and will help to offset calcium losses (a tablespoon has only 6 calories, but 19 milligrams of calcium).

Avoid sugar in your coffee. "A teaspoon of sugar contains 16 calories. It may not sound like much, but if you add two teaspoons to your brew and drink a few cups per day, the calories add up," she said.

The-CNN-Wire & 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Originally posted here:
The healthiest way to brew your coffee -- and possibly lengthen your life - WDJT

Do You Want to Die in an I.C.U.? Pandemic Makes Question All Too Real – The New York Times

Earlier this month, Cheryl Goldman, a retired high school teacher living on Long Island, called her son, Edo Banach, in Maryland. It seemed a routine chat until Ms. Goldman announced that if she became ill with Covid-19, she would decline a ventilator.

Im her health care proxy, said Mr. Banach, who happens to be the president of the National Hospice and Palliative Care Organization. Her perspective was, whats the point? In all likelihood its not going to help, and shed be taking a vent away from someone else.

At 69, Ms. Goldman has emphysema and already relies on supplemental oxygen. She told me that shed been following the news, including the grim statistics for older adults with chronic illnesses who require ventilators during extended stays in intensive care.

In such cases, the number who leave the hospital is low, and its lower for someone with health problems like me, she said. She also feared being separated from her family during a hospitalization and wanted, instead, to remain at home with hospice care. Its a pragmatic decision.

Mr. Banach, leading the response of about a thousand hospices nationwide that are facing heightened demand and bracing for worse, appreciated her forthrightness. Its the kind of conversation everyone should be having with their loved ones, he said.

In the best of times, it can be tough to get Americans to discuss and document their end-of-life wishes. Depending on the study, a third to two-thirds of adults havent drafted advance directives, the documents that outline which medical treatments they would accept or refuse and designate a decision maker to act on their behalf if theyre incapacitated.

People think, Ill deal with it in the future, Mr. Banach said. But for thousands of older adults, the future may have arrived.

To date, theres no clear evidence that older people are more apt to contract the new coronavirus, said Dr. Douglas White, a critical care specialist and the director of the Program on Ethics and Decision Making at the University of Pittsburgh School of Medicine.

What we do know is that older individuals are more likely to experience very severe disease if they do become infected, he said. The data are sobering.

Thats partly because most older adults have chronic conditions heart or lung disease, diabetes, high blood pressure known to intensify the viruss effects. And they have less physiologic reserve less ability to rebound from an overwhelming illness, Dr. White explained.

When seniors and their families engage in whats called advance-care planning, they often focus on the D.N.R. question whether patients would want to be resuscitated after cardiac arrest.

But because Covid-19 is a respiratory disease, the more pressing question will likely be whether a hospitalized patient whos seriously ill will accept intubation and ventilation.

That initially involves a tube inserted down the throat, connected to a ventilator that pushes air into the lungs. When a patient has spent two weeks on a vent, doctors commonly perform a tracheostomy, creating a surgical opening in the windpipe that replaces the swallowed tube.

Long before the virus erupted, among people over 66 who spent 14 days in an I.C.U. on a ventilator, 40 percent died within a year of discharge. Now, those numbers are too rosy for Covid, Dr. White said, citing findings from Italy and Britain, where more than half of older patients on prolonged ventilation died.

A just-published JAMA article looked at coronavirus patients admitted to Northwell Health hospitals in and around New York City. Excluding those still hospitalized after the monthlong study, the mortality rate among patients over age 65 exceeded 26 percent, and almost all patients over 65 who needed mechanical ventilation during that period died.

That data can prompt frank exchanges. If a patient is elderly and has significant medical issues, Ill explain that a large proportion of people who become ill with Covid-19 and need a ventilator unfortunately will not survive, said Dr. Kosha Thakore, the director of palliative care at Newton-Wellesley Hospital in Massachusetts.

Moreover, longevity is not the only priority, and sometimes not the primary one, for older people considering medical options. What will life look like if they do survive?

After elderly people have been on a ventilator, theyve often already developed physical debilitation, difficulty swallowing, bedsores, Dr. Thakore explained. They frequently cycle in and out of hospitals with complications. Their deficits can be physical or cognitive or both, and are often permanent.

Even pre-Covid, after 14 days on a ventilator in an I.C.U., only about one in five older discharged patients went home. The others end up in nursing homes, Mr. Banach said. Some may later go home, and some will die in the nursing home.

Though older adults with Covid-19 may not require hospitalization or ventilation, the decisions they face if they do highlight the importance of reviewing advance directives.

A new study in JAMA Internal Medicine questioned 180 patients over age 60 with serious illnesses; most said they would trade a year of life if that meant they could avoid dying in an I.C.U. on life support.

But that kind of aggressive care is exactly what they might receive. If you dont let the system know your wishes, the system takes over, Mr. Banach pointed out. Family members can feel lingering trauma if theyre forced to make life-or-death decisions for loved ones who never discussed what they wanted.

Many older patients weve encountered with Covid-19 have opted not to undergo ventilation and an I.C.U., Dr. White said. No one should impose that on a patient, though if theres true scarcity, that may arise. But patients might choose it for themselves.

If older people have paperwork stashed in a drawer or safe, now is the time to unearth it and see if their instructions still reflect their values. If so, scan the document and send it to family members and doctors, Mr. Banach advised.

But for those who never got around to drawing up advance directives, appointing a decision maker and telling that person whats acceptable and whats not is ultimately more crucial. In emergencies, doctors probably wont flip through documents to learn patients wishes; theyll ask family or friends.

Mr. Banachs counsel: Take out your phone and do a video selfie: This is who I am. This is the date. This is what I want. Send it to your friends and relatives. Thats enough.

Many hospitals and health systems have developed workarounds when documents require signatures or witnesses; some are also doing palliative-care visits via telemedicine.

Dr. Gregg VandeKieft, a palliative care specialist with Providence Health on the West Coast, recently spent half an hour on Zoom talking with a patients sons about her end-of-life care. Dr. VandeKieft and a nurse were in Olympia, Wash.; one son was in Alaska and two elsewhere in Washington. It felt not all that different than if wed been in the same room, Dr. VandeKieft said.

The coronavirus pandemic may spur more such conversations. In Los Angeles recently, Brie Loskota and her husband contacted close family friends, a couple in their 70s, asking about their well-being, offering to FaceTime, and then inquired: If you got sick, is there anything we should know?

The older couple, one of whom has a neurodegenerative disease and has already experienced mechanical ventilation, responded that they both wanted to avoid hospitalization and to die at home.

It was a relief to be told, said Ms. Loskota. Its not less heartbreaking, but it lets us make a decision with them in mind. It led my husband and me to talk about it for ourselves. Theyre in their 40s and have not yet drafted advance directives.

Read the rest here:
Do You Want to Die in an I.C.U.? Pandemic Makes Question All Too Real - The New York Times

In Austria under COVID, the Jewish community is thriving and the gay community is struggling – JTA News

VIENNA (JTA) It takes a crisis to show that not all communities are hewn from the same clay. Death, Saul Bellow wrote in Humboldts Gift, is the dark backing that a mirror needs if we are to see anything.

I have spent the last few years observing, reporting on and writing about Jewish and gay communal life. To watch both simultaneously as this coronavirus crisis unfolds is to witness a Jewish community bound together, finding ways to weather the storm, to maintain a sense of continuity, while the gay community loosens rapidly and functionally ceases to exist.

A disaster has befallen the world. To unlock ones phone in the morning is to hook oneself up to an IV of bad news both around the world and close to home.

A few weeks ago I opened Facebook to discover that this citys Jewish community, the IKG, had confirmed its first victim of the coronavirus and was reducing social contact in kosher supermarkets, one of the last forums of Jewish communal life to remain somewhat open. I receive a daily email from the Board of Deputies of British Jews with that days body count.

As in so many places, congregations of five or more people have been banned, synagogues and Jewish schools were closed down, and prayer services and lectures have been canceled.

But Judaism has tools to weather interruptions like these. As Amos Oz and Fania Oz-Salzberger noted in Jews and Words, Judaisms longevity has hinged on the written word a lineage of literacy, with tradition and knowledge preserved in books and passed down through their interpretation.

What kept the Jews going were the books, they wrote.

Whats more, Viennas chief cantor, Shmuel Barzilai, is live broadcasting morning, afternoon and evening prayers on Facebook. Since the Seitenstettengasse Temple shut its doors, shiurim on the weekly Torah portions have been sent out to community members via email, and services before and after Shabbat have been transmitted via live feed.

Jewish communal life in Europe, with its membership and dues, comes with a certain sense of belonging and shared responsibility. Jewish students are organizing grocery and medicine deliveries for the communitys elderly and vulnerable members. The IKG has made a $275,000 fund available to members in financial need and has been sending out coronavirus-related information in Hebrew and Russian, reaching those whose grasp of German is weak and may otherwise have been passed over.

For the gay community, the change in social relations was as abrupt. Bars have shuttered. Apps like Grindr are telling users to stay home. Vienna Pride, which was due to take place in June, is one of at least 188 pride festivals from Los Angeles to London to Sydney to be canceled or postponed. With museums, theaters and galleries closed to the public, so much hard work by gay artists and performers will go unseen and unheard. And NGOs that operate refuges and drop-in centers can no longer do their work.

That, combined with the effects of social distancing, has placed some young gay people in an especially vulnerable position. Sam, 23, told the BBC of his experience of having to move back home with his strict Christian parents in order to self-isolate.

I see on social media that people are so busy filming home workouts, and holding online parties, that they dont realize there are people like me struggling to stay alive right now, he said.

Paul Martin, chief executive of the British LGBT Foundation, said that many people like Sam now feel they have nobody to turn to.

In the absence of the same infrastructure and traditions on which the Jewish community can lean, faced with an illness that demands social distancing, gay life broke down and became atomized faster than I ever could have imagined. It is not that the gay community is without its attachments and rituals. But its usual expressions of joy, play and solidarity are hard to express when the world is sheltering in place.

Now more than ever, its clear that a community based on a common characteristic, the expression of which is primarily achieved through social contact and political activism, is not the same as a peoplehood bound together by thousands of years of religious tradition and shared civic bonds. The latter offers a sense of stability and continuity, of togetherness and a way through this particular disaster that the other, sadly, cannot.

The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of JTA or its parent company, 70 Faces Media.

Continue reading here:
In Austria under COVID, the Jewish community is thriving and the gay community is struggling - JTA News

Marginalisation of indigenous healers – News24

The outbreak of the deadly Covid-19 coronavirus pandemic poses a serious threat to human life and socioeconomic order in the world today.

In South Africa, the virus has also exposed the continuing marginalisation of indigenous healers as key social partners as the democratic state responds to the crisis.

Nevertheless, one must commend the swift response to the deepening health calamity shown by the government, as well as other key facets of civic society, organised business, labour and faith-based organisations.

The position taken by the Ghanaian government in working closely with the countrys indigenous healers should be exemplary to South Africa.

Recognition from our own government both in practice and attitude the value of our indigenous knowledge systems of spirituality, medicine and healing by the government would be an affirmation of our African identity. Matters of holistic health cannot be the sole domain of Western medicine.

Our role, for instance, in educating fellow practitioners and broader society in dealing with of this deadly pandemic is vital. It must be incorporated into the public awareness value chain, and be properly defined by government through a consultative and mutually respectful process.

As we seek balance in these difficult times, let us ask our living-dead to provide sanctuary and ammunition in the fight against a devastating disease of both the body and spirit.

Over the years, our sector has done its best to comply with various pieces of legislation in health, human rights, education and ethical business conduct. We also continue to devise plans for rooting out fraudulent practitioners from our ranks. We always urge people to be vigilant and to report abuse to law enforcement agencies.

Governments reluctance to consult widely with African indigenous spiritualists, medicine specialists and healers (and the condescension of Western healthcare practitioners towards our sector) during the fight against the pandemic is regretful, since there is a great deal of research to support our relevance to millions of people.

The main point is not to attack either Western, Eastern, African or other indigenous medical practices, but create a more inclusive approach towards holistic health and healing. As citizens, it is our democratic right to openly raise issues of concern and suggest a negotiated way forward.

It is a serious violation of our rights and dignities to be cast out, as if our spheres of medicine were inferior and unlikely to contribute positively to the fight against the immense and complex burdens brought on our nation by Covid-19.

The socioeconomic devastation that is anticipated in the wake of the pandemic is a big indicator that, unless traditional health practitioners are given their due recognition, they could easily fall into the category of affected groups who are simply not covered by current social rescue initiatives government has introduced.

The case can be illustrated further by revealing that, in the current climate of socioeconomic uncertainty, practitioners of indigenous African medicine and spirituality are affected in varied ways.

The sector include two broad lines of specialists: qualified healers and apprentice healers. The latter group often comprises people whose professions and careers may be in abeyance, because their ancestral calling has been disrupted or their regular sources of income have stopped.

Raising these issues openly is also an attempt to broaden understanding of our value in the overall holistic health and well-being of our society, especially given so many misunderstandings and outright distortions of who we are and what we do.

Our ancestors are first and foremost working through us and our internal cleansing so that we, in turn, become eligible vessels for the actualisation of healing powers through our minds and bodies.

Mkhize

Even in trying times such as these, we must fully embrace our ancestors and do whatever is possible and legally permissible to call for their appeasement and abiding wisdom, as we have done in times of famine, drought and other life-threatening disasters. The Covid-19 pandemic is another opportunity for all of us to become more grounded Africans and work harder at establishing a deeper connection with our beloved living-dead.

Those in our ancestral universe who love us must be central pillars in our prayers for wisdom and protection. This is the time to meditate deeply, as individuals and families, on the key life-giving values and lived experiences we know our ancestors regarded as sacred for blessings and longevity. As we seek balance in these difficult times, let us ask our living-dead to provide sanctuary and ammunition in the fight against a devastating disease of both the body and spirit.

Undoubtedly, our initiates at this time are facing insurmountable challenges, especially since the current lockdown regulations compel them to return home, whether their initiation programmes are complete or not. Some initiates, upon their return home, face ostracism, various forms of abuse and mistrust.

There is also a common misunderstanding in communities that tends to negatively pathologise a persons ancestral calling. What is often misread is the fact that what may symptomatically present itself as an illness (in the ordinary way Western medicine defines illness) is in essence an uncomfortable, yet transitional phase towards self-healing mandated by the ancestors.

Our ancestors are first and foremost working through us and our internal cleansing so that we, in turn, become eligible vessels for the actualisation of healing powers through our minds and bodies.

The burdened and contested, but respected, life of the great Sanusi Credo Muthwa embodies these aspects of initial and to some degree perennial illness as a precondition for serving others as a healer.

Although his life was not one of wealth, many people in South Africa and across the world derived healing from the immeasurable gifts bestowed on him by God through his ancestors.

In 2018, certain aspects of the Traditional Health Practitioners (THP) Act came into force. Although the process was long and arduous, the progress is welcome, as it recognises that there are diverse healing practices in the country, not just Western medicine.

The act defines four categories of THPs: diviners (sangomas), herbalists (inyanga), traditional birth attendants (ababelethisi) and traditional surgeons (ingcibi).

There is no doubt that a more inclusive and mutually respectful working relationship between traditional health practitioners and the peoples government would benefit everyone. We, too, are ready to serve and play our part in the fight against the deadly coronavirus pandemic.

Akwande!

*Mkhize is president and founder of Umsamo Institute/Isigodlo Sase Mlambomunye

Read more here:
Marginalisation of indigenous healers - News24

Assessing the Fallout From the Coronavirus Pandemic Spinal Muscular Atrophy Medicine Market Global Industry Analysis, Trends and Forecast, 2019-2027…

Analysis of the Global Spinal Muscular Atrophy Medicine Market

The presented report on the global Spinal Muscular Atrophy Medicine market offers valuable insights related to the future prospects of the Spinal Muscular Atrophy Medicine market. The study evaluates the various parameters that are expected to influence the growth of the Spinal Muscular Atrophy Medicine market over the forecast period including the current trends, regulatory framework, and evolving policy structure across different regions. The impact of the COVID-19 pandemic on the global Spinal Muscular Atrophy Medicine market along with the projected plan of action is included in the presented study.

As per the study, the Spinal Muscular Atrophy Medicine market is poised to exceed the value of ~US$XX by the end of 2019 and grow at a CAGR of ~XX% during the considered forecast period, 20XX-20XX. The growth opportunities for established and emerging market players, drivers of the market, and existing challenges in the Spinal Muscular Atrophy Medicine market are thoroughly analyzed. Although the market is expected to witness a slow growth rate in the first half of the forecast period due to the COVID-19 pandemic, market growth is expected to gather momentum in the second half.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2633762&source=atm

Spinal Muscular Atrophy Medicine Market Bifurcation

By Region

The regional assessment included in the Spinal Muscular Atrophy Medicine market sheds light on the scenario of the Spinal Muscular Atrophy Medicine market in various geographies. The scope of growth, market share, size, and future prospects of the Spinal Muscular Atrophy Medicine market in each regional market is illustrated in the report along with informative graphs and figures.

By Product Type

The product adoption assessment sheds light on the pricing structure, supply-demand ratio and the innovations involved in each product.

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by Type, the Spinal Muscular Atrophy Medicine market is segmented intoLMI-070ND-602NT-1654NusinersenNXD-30001Others

Segment by ApplicationHospitalClinicOthers

Global Spinal Muscular Atrophy Medicine Market: Regional AnalysisThe Spinal Muscular Atrophy Medicine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Spinal Muscular Atrophy Medicine market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal Spinal Muscular Atrophy Medicine Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.The major players in global Spinal Muscular Atrophy Medicine market include:Astellas Pharma Inc.AveXis, Inc.Bioblast Pharma Ltd.Cytokinetics, Inc. 24F. Hoffmann-La Roche Ltd.GenethonGenzyme CorporationGMP-Orphan SASIonis Pharmaceuticals, Inc.Longevity Biotech, IncNeurodyn Inc.Neurotune AGNovartis AGSarepta Therapeutics, Inc.Voyager Therapeutics, Inc.Vybion, Inc.WAVE Life Sciences Ltd.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2633762&source=atm

Competitive Assessment

The completion landscape of the Spinal Muscular Atrophy Medicine market is accurately depicted in the report. The report includes the company profiles of some of the leading companies in the Spinal Muscular Atrophy Medicine market wherein the product portfolio, pricing structure, and market share of each company is provided.

Vital Information that can be drawn from the Spinal Muscular Atrophy Medicine Market Report

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2633762&licType=S&source=atm

The report aims to address the following queries related to the Spinal Muscular Atrophy Medicine market:

Read the rest here:
Assessing the Fallout From the Coronavirus Pandemic Spinal Muscular Atrophy Medicine Market Global Industry Analysis, Trends and Forecast, 2019-2027...

A gene that could unlock the mysteries of COVID-19 – ModernHealthcare.com

The team's results, posted as a preprint in BioRxiv earlier this month, proposed a handful of ACE2 variants suspected of boosting SARS-CoV-2 binding and, potentially, host susceptibility, along with several variants predicted to dial down ACE2 interactions with the viral spike protein that may be protective.

"What we can conclude is that this new virus has evolved new modality to interact with the ACE2 receptor," Jura noted. "Unfortunately, it seems like there are polymorphisms in the human population that will make some individuals more susceptible to binding this virus because these mutations are enhancing this unique part of the interface."

Seshagiri noted that such insights might make it possible to design potential therapeutic versions of ACE2 that are particularly adept at binding coronavirus spike proteins, thereby preventing the viruses from interacting with an individual's own ACE2 receptors, for example.

In a recent Cell paper, a team from Sweden, Spain, Austria, and Canada proposed its own strategy for engineering soluble, clinical-grade forms of the human ACE2 protein that appeared to dial down early-stage infections by SARS-CoV-2 in otherwise susceptible cell types.

"We are not the first to come up with the idea of saying ACE2 could be a therapeutic," he said, though he suggested that engineering soluble forms of the receptors protein that bind well to SARS-CoV-2 may serve as a strategy for "future proofing" against the emergence of these and other related viruses down the road.

The researchers plan to profile ACE2 polymorphisms in still more human samples for the final version of the study, which will likely be submitted for peer review in the coming weeks, Seshagiri said.

He and MedGenome CEO Rayman Mathoda noted that the diagnostic company, which is active in India and other emerging markets, is also a founding member of a GenomeAsia 100K project.

"We've made a very intentional effort to build on a data-focused set of efforts, where we take our proprietary data as we grow, but build in other data source," Mathoda said.

The investigators are not alone in attempting to establish a baseline understanding of ACE2 variation across and within populations.

At the University of Siena in northern Italy, Alessandra Renieri and her colleagues have been delving into ACE2 genetic variation using available exome sequences for some 7,000 healthy participants in the Network of Italian Genomes project. As they reported in a preprint posted to MedRxiv in early April, the investigators saw significant variation in ACE2 in that retrospective dataset, including both common and rare, missense variants predicted to influence the protein's stability and its interactions with the coronavirus viral spike.

"There is pretty wide genetic variability," Renieri said. "There are both polymorphisms, so variants found in a percentage of the population, and there are also rare variants a lot of rare variants."

It may be possible for the individual centers participating in the Network of Italian Genomes to recontact individuals in the future to try to find out who became infected with SARS-CoV-2 and to assess ACE2 variation alongside clinical outcomes, Renieri noted, though she cautioned that "ACE2 is just one of the many genes that could be involved."

For the reCOVID project, members of the team are seeking funding through the European Commission's Innovative Medicines Initiative IMI2 call for proposals to do functional analyses on ACE2 and other genes, for example, in the hopes of developing candidate therapeutics.

Renieri is also part of a team that been working since mid-March to prospectively collect samples from 2,000 COVID-19 patients at least 21 different hospitals in Italy as part of the GEN-COVID study, part of the COVID-19 Host Genetics Initiative.

For that project, researchers in Italy will use whole-exome sequencing to assess patient samples collected in conjunction with very detailed clinical information, she explained, while collaborators in Finland will genotype the samples for a related genome-wide association study.

Continued here:
A gene that could unlock the mysteries of COVID-19 - ModernHealthcare.com

What Animal Alliance of Canada would like everyone to know about COVID-19 Vaccine Testing – GlobeNewswire

TORONTO, April 21, 2020 (GLOBE NEWSWIRE) -- Along-standing regulatory requirementto bringvaccinesto marketinvolvestesting them onanimal models prior to clinical trials with humans.Although thisseems like a very good safety measure for humans,most people donot know that90% of whatworked on animal models didn't workforhumans andinsomecaseseven caused harm.

This acceptance of a 10% predictive rate using animal models is in stark contrast with the85-90% predictive rate using modern vitro technologies. According to veterinarian Dr. Andre Menache, "the requirement for testing on animal models dates back to theNuremberg Codes of 1947 and is still the norm in national and international legislation today."

Liz White, Director of Animal Alliance of Canada, a national animal advocacyorganization, states, "What most people do not know is that mice are resistant to the COVID-19 virus. Mice are forced through genetic engineering to have the human version of the enzyme that causes COVID-19. Researchers then use the mice to test a vaccine in order tomeet regulatory requirements before starting clinical trials on humans. This process seems scientifically flawed."

We need a vaccine to combat COVID-19 (SARS-CoV2), a virus globally ravaging populations and economies today. Consequently, we need to discuss and challenge testing on animal models when we should be using human relevant models. According to Dr. Menache, "there are some high-performance technologies of the 21st century we can use for example 'MIMIC' (Modular IMune In vitro Construct). It's an in vitro model of the human immune system." According to Michael Rivard, vice president of corporate development at VaxDesign, "the information you get from this type of test is far beyond what you'd get out of a mouse study both because it's humans and because you can see the effect across a spectrum of genotypes".

Because we're in an emergency situation, researchers decided to test new treatments directly on volunteer patients. Importantly, these are drugs that have already been tested on animals for their intended uses.

In the recent past, there have been other COVID related viruses, like SARS, for which we still don't have a vaccine. Dr. Menache states, "Perhaps the COVID-19 pandemic will help us to question some of our outdated scientific practices as well as the obsolete regulations that still impose them."

We urge the Trudeau government and theresearch community to establish a research institution whose mandate is the exploration and development of human-relevant research not using animal models to create a better future for all of us,said White. We need to move our research objectives out of the 19th century and into the 21st century.

Liz White, Director, Animal Alliance of CanadaCell (Canada): 416-809-4371Email: liz@animalalliance.ca

Dr. Andre Menache, CEO of Antidote Europe, is a European Veterinary Specialist in Animal Welfare Science, Ethics and Law and a member of theEuropean College of Animal Welfare and Behavioural Medicine. He is a zoologist and a veterinary surgeon with a particularinterest in medical law and was instrumental in amending the Declaration of Helsinki (DH) see DH here:https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Dr. Menache,BSc (zoology), BSc(Hons), BVSc, MRCVSCell (France):+33 6 23 42 62 95 Email:andre.menache@gmail.com

Excerpt from:
What Animal Alliance of Canada would like everyone to know about COVID-19 Vaccine Testing - GlobeNewswire

Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race – Salon

There has beenno scientific findingthat the novel coronavirus was bioengineered, but its origins are not entirely clear. Deadly pathogens discovered in the wild are sometimesstudied inlabs and sometimes made more dangerous. That possibility, and other plausible scenarios, have been incorrectly dismissed in remarks by some scientists andgovernment officials, and in the coverage of most major media outlets.

Regardless of the source of this pandemic, there is considerable documentation that a global biological arms race going on outside of public view could produce even more deadly pandemics in the future.

While much of the media and political establishment have minimized the threat from such lab work, some hawks on the American right like Sen. Tom Cotton, R-Ark., have singled outChinese biodefense researchers as uniquely dangerous.

But there is every indication that U.S. lab work is every bit as threatening as that in Chinese labs. American labs also operate insecret, and are also known to beaccident-prone.

The current dynamics of the biological arms race have been driven by U.S. government decisions that extend back decades. In December 2009, Reuters reported that the Obama administration was refusing even to negotiate the possible monitoring of biological weapons.

Advertisement:

Much of the left in the U.S. now appears unwilling to scrutinize the origin of the pandemic or the wider issue of biowarfare perhaps because portions of the anti-Chinese right have been sovocal in making unfoundedallegations.

Governments that participate in such biological weapon research generally distinguish between "biowarfare" and "biodefense," as if to paint such "defense" programs as necessary. But this is rhetorical sleight-of-hand; the two concepts are largely indistinguishable.

"Biodefense" implies tacit biowarfare, breeding more dangerous pathogens for the alleged purposeof finding a way tofightthem. While this work appears to have succeeded in creating deadly and infectious agents, including deadlier flu strains, such "defense" research is impotent in its ability to defend us from this pandemic.

The legal scholar who drafted the main U.S. law on the subject, Francis Boyle, warned in his 2005 book "Biowarfare and Terrorism" that an "illegal biological arms race with potentially catastrophic consequences" was underway, largely driven by the U.S. government.

For years,many scientistshave raised concerns regarding bioweapons/biodefense lab work, and specifically aboutthe fact that huge increases in funding have taken place since 9/11. This was especially true afterthe anthrax-by-mail attacks that killed five people in the weeks after 9/11, which the FBI ultimately blamed on a U.S. government biodefense scientist.A 2013 study found that biodefense funding since2001 hadtotaled at least $78 billion, and more has surely been spent since then. This has led to aproliferation of laboratories, scientists and new organisms, effectively setting off a biological arms race.

Following the Ebola outbreak in west Africa in 2014, the U.S. governmentpaused fundingfor what are known as "gain-of-function" research on certain organisms. This work actually seeks to make deadly pathogensdeadlier, in some cases making pathogens airborne thatpreviously were not. With little notice outside the field, the pause on such research was lifted in late 2017.

During this pause, exceptions for funding were made for dangerous gain-of-function lab work. This included work jointly done by U.S. scientists from the University of North Carolina, Harvard and the Wuhan Institute of Virology. This work which had funding from USAID and EcoHealth Alliance not originally acknowledged was published in2015 in Nature Medicine.

A different Nature Medicine article about the origin of the current pandemic,authored by five scientists andpublished on March 17,has been touted by major media outlet and some officials including current National Institutes of Health directorFrancis Collins as definitively disproving a lab origin for the novel coronavirus. That journal article, titled "The proximal origin of SARS-CoV-2," stated unequivocally: "Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus." This is a subtly misleading sentence. While the scientists state that there is no known laboratory "signature" in the SARS-Cov-2 RNA, their argument fails to take account of other lab methods that could have created coronavirus mutations without leaving such a signature.

Indeed, there is also thequestion of conflict of interest in the Nature Medicine article. Some of the authors of that article, as well as aFebruary 2020Lancet letter condemning "conspiracy theories suggesting that COVID-19 does not have a natural origin" which seemed calculated to minimize outside scrutiny of biodefense lab work have troubling ties to thebiodefense complex,as well as to the U.S. government. Notably, neither of these articles makes clear that a virus can have a natural originand then be captured and studied in a controlled laboratory setting before being let loose, either intentionally or accidentallywhichis clearly a possibility in the case of the coronavirus.

Facts as "rumors"

This reporter raised questions about the subject at a news conference with a Center for Disease Control (CDC) representative at the now-shuttered National Press Club on Feb. 11. I asked if it was a "complete coincidence" that the pandemic had started in Wuhan, the only place in China with a declared biosafety level 4 (BSL4) laboratory. BSL4 laboratories have the most stringent safety mechanisms, but handle the most deadly pathogens. As I mentioned, it was oddthat the ostensible origin of the novel coronavirus was bat caves in Yunnan province more than 1,000 miles from Wuhan. I noted that "gain-of-function" lab work can results in more deadly pathogens, and that major labs, including some in the U.S., have had accidental releases.

CDC Principal Deputy Director Anne Schuchat saidthatbased on the information she had seen, the virus was of "zoonotic origin." She also stated, regarding gain-of-function lab work, that it is important to "protect researchers and their laboratory workers as well as the community around them and that we use science for the benefit of people."

I followed up by asking whether an alleged natural origin did not preclude the possibility that this virus came through a lab, since a lab could have acquired a bat virus and been working on it. Schuchat replied to the assembled journalists that "it is very common for rumors to emerge that can take on life of their own," but did not directly answer the question. She noted that in the 2014 Ebola outbreak some observers had pointed to nearby labs as the possible cause, claiming this "was a key rumor that had to be overcome in order to help control the outbreak." She reiterated: "So based on everything that I know right now, I can tell you the circumstances of the origin really look like animals-to-human. But your question, I heard."

This is no rumor. It's a fact: Labs work with dangerous pathogens. The U.S. and China each have dual-use biowarfare/biodefense programs. China has major facilities at Wuhan a biosafety level 4 lab and a biosafety level 2 lab. There are leaks from labs. (See "Preventing a Biological Arms Race," MIT Press, 1990, edited by Susan Wright; also, a partial review in Journal of International Law from October 1992.)

Much of the discussion of this deadly serious subject is marred with snark that avoids or dodges the "gain-of-function" question. ABC ran a story on March 27 titled "Sorry, Conspiracy Theorists. Study Concludes COVID-19 'Is Not a Laboratory Construct.'" That story did not address the possibility that the virus could have been found in the wild, studied in a lab and thenreleased.

On March 21, USA Today published a piece headlined "Fact Check: Did the Coronavirus Originate In a Chinese Laboratory?" and rated it "FALSE."

That USA Today story rel
ied on the Washington Post, which publishedawidely cited article onFeb.17headlined,"Tom Cotton keeps repeating a coronavirus conspiracy theory that was already debunked." That article quoted public comments fromRutgers University professor of chemical biology Richard Ebright, but out of context and only in part. Specifically, the story quoted from Ebright's tweet that the coronavirus was not an "engineered bioweapon." In fact, his full quote included the clarification that the virus could have "entered human population through lab accident." (An email requesting clarification sent toPost reporterPaulina Firoziwas met with silence.)

Bioengineered From a lab

Other pieces in the Post since then (some heavily sourced to U.S. government officials) have conveyed Ebright's thinking, but it gets worse. In a private exchange, Ebright who, again, has said clearly that the novel coronavirus was not technically bioengineered using known coronavirus sequences stated that other forms of lab manipulation could have beenresponsible for the current pandemic. This runs counter to much reporting, which is perhaps too scientifically illiterate to perceive the difference.

In response to the suggestion that the novel coronavirus could have come about through various methodsbesides bioengineering made by Dr. Meryl Nass, who has done groundbreaking work on biowarfareEbright responded in an email:

The genome sequence of SARS-CoV-2 has no signatures of human manipulation.

This rules out the kinds of gain-of-function (GoF) research that leave signatures of human manipulation in genome sequences (e.g., use of recombinant DNA methods to construct chimeric viruses), but does not rule out kinds of GoF research that do not leave signatures (e.g., serial passage in animals). [emphasis added]

Very easy to imagine the equivalent of the Fouchier's "10 passages in ferrets" with H5N1 influenza virus, but, in this case, with 10 passages in non-human primates with bat coronavirus RaTG13 or bat coronavirus KP876546.

That last paragraph is very important. It refersto virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam, who performed research on intentionally increasing rates of viralmutation rate by spreading a virus from one animal to another in a sequence.The New York Times wrote about this in an editorial in January 2012, warning of "An Engineered Doomsday."

"Now scientists financed by the National Institutes of Health" have created a "virus that could kill tens or hundreds of millions of people" if it escaped confinement, the Times wrote. The story continued:

Working with ferrets, the animal that is most like humans in responding to influenza, the researchers found that a mere five genetic mutations allowed the virus to spread through the air from one ferret to another while maintaining its lethality. A separate study at the University of Wisconsin, about which little is known publicly, produced a virus that is thought to be less virulent.

The word "engineering" in the New York Times headline is technically incorrect, sincepassing a virus through animals is not "genetic engineering." This same distinction has hindered some from understanding the possible origins of the current pandemic.

Fouchier's flu work, in which an H5N1 virus was made more virulent by transmitting it repeatedly between individual ferrets, briefly sent shockwaves through the media. "Locked up in the bowels of the medical faculty building here and accessible to only a handful of scientists lies a man-made flu virus that could change world history if it were ever set free," wrote Science magazine in 2011 in a story titled "Scientists Brace for Media Storm Around Controversial Flu Studies." It continues:

The virus is an H5N1 avian influenza strain that has been genetically altered and is now easily transmissible between ferrets, the animals that most closely mimic the human response to flu. Scientists believe it's likely that the pathogen, if it emerged in nature or were released, would trigger an influenza pandemic, quite possibly with many millions of deaths.

In a 17th floor office in the same building, virologist Ron Fouchier of Erasmus Medical Center calmly explains why his team created what he says is "probably one of the most dangerous viruses you can make" and why he wants to publish a paper describing how they did it. Fouchier is also bracing for a media storm. After he talked to ScienceInsider yesterday, he had an appointment with an institutional press officer to chart a communication strategy.

Fouchier's paper is one of two studies that have triggered an intense debate about the limits of scientific freedom and that could portend changes in the way U.S. researchers handle so-called dual-use research: studies that have a potential public health benefit but could also be useful for nefarious purposes like biowarfare or bioterrorism.

Despite objections, Fouchier's article was published by Science in June 2012. Titled "Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets," it summarized how Fouchier's research team made the pathogen more virulent:

Highly pathogenic avian influenza A/H5N1 virus can cause morbidity and mortality in humans but thus far has not acquired the ability to be transmitted by aerosol or respiratory droplet ("airborne transmission") between humans. To address the concern that the virus could acquire this ability under natural conditions, we genetically modified A/H5N1 virus by site-directed mutagenesis and subsequent serial passage in ferrets. The genetically modified A/H5N1 virus acquired mutations during passage in ferrets, ultimately becoming airborne transmissible in ferrets.

In other words, Fouchier's research took a flu virus that did not exhibit airborne transmission, then infected a number of ferrets until it mutated to the point that it was transmissible by air.

In thatsame year, 2012, asimilar studyby Yoshihiro Kawaoka of the University of Wisconsin was published in Nature:

Highly pathogenic avian H5N1 influenza A viruses occasionally infect humans, but currently do not transmit efficiently among humans. ... Here we assess the molecular changes ... that would allow a virus ... to be transmissible among mammals. We identified a ... virus ... with four mutations and the remaining seven gene segments from a 2009 pandemic H1N1 virus that was capable of droplet transmission in a ferret model.

In 2014, Marc Lipsitch of Harvard and Alison P. Galvani of Yale wrote regarding Fouchier and Kawaoka's work:

Recent experiments that create novel, highly virulent and transmissible pathogens against which there is no human immunity are unethical ... they impose a risk of accidental and deliberate release that, if it led to extensive spread of the new agent, could cost many lives. While such a release is unlikely in a specific laboratory conducting research under strict biosafety procedures, even a low likelihood should be taken seriously, given the scale of destruction if such an unlikely event were to occur. Furthermore, the likelihood of risk is multiplied as the number of laboratories conducting such research increases around the globe.

Given this risk, ethical principles, such as those embodied in the Nuremberg Code, dictate that such experiments would be permissible only if they provide humanitarian benefits commensurate with the risk, and if these benefits cannot be achieved by less risky means.

We argue that the two main benefits claimed for these experiments improved vaccine design and improved interpretation of surveillance are unlikely to be achieved by the creation of potential pandemic pathogens (PPP), often termed "gain-of-function" (GOF) experiments.

There may be a widespread notion that there is scientific consensus that the pandemic did not come out of a lab. But in factmany of the most knowledgeable scientists in the field are notably silent. This includes Lipsitch at Harvard, Jonathan A. King at MITand many others.

Just last year, Lynn Klotz of the Center for Arms Control and Non-Prolife
ration wrote a paperin the Bulletin of the Atomic Scientistsentitled "Human Error in High-biocontainment Labs: A Likely Pandemic Threat." Wrote Klotz:

Incidents causing potential exposures to pathogens occur frequently in the high security laboratories often known by their acronyms, BSL3 (Biosafety Level 3) and BSL4. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab; lab workers with such infections will leave work carrying the pathogen with them. If the agent involved were a potential pandemic pathogen, such a community release could lead to a worldwide pandemic with many fatalities. Of greatest concern is a release of a lab-created, mammalian-airborne-transmissible, highly pathogenic avian influenza virus, such as the airborne-transmissible H5N1 viruses created in the laboratories of Ron Fouchier in the Netherlands and Yoshihiro Kawaoka in Madison, Wisconsin.

"Crazy, dangerous"

Boyle, a professor of international law at the University of Illinois, has condemned Fouchier, Kawaoka and others including at least one of the authors of the recent Nature Medicine article in the strongest terms, calling such work a "criminal enterprise." While Boyle has been embroiled in numerous controversies, he's been especially dismissed by many on this issue. The "fact-checking" websiteSnopeshas described him as "a lawyer with no formal training in virology" without noting that he wrote the relevant U.S. law.

As Boyle saidin 2015:

Since September 11, 2001, we have spent around $100 billion on biological warfare. Effectively we now have an Offensive Biological Warfare Industry in this country that violates theBiological Weapons Conventionand myBiological Weapons Anti-Terrorism Act of 1989.

The law Boyle drafted states: "Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States."

Boyle also warned:

Russia and China have undoubtedly reached the same conclusions I have derived from the same open and public sources, and have responded in kind. So what the world now witnesses is an all-out offensive biological warfare arms race among the major military powers of the world: United States, Russia, Britain, France, China, Israel, inter alia.

We have reconstructed the Offensive Biological Warfare Industry that we had deployed in this county before its prohibition by the Biological Weapons Convention of 1972, described by Seymour Hersh in his groundbreaking expose "Chemical and Biological Warfare: America's Hidden Arsenal." (1968)

Boyle now states that he has been "blackballed" in the media on this issue, despite his having written the relevant statute. The group he worked with on the law, the Council for Responsible Genetics, went under several years ago, making Boyle's views against "biodefense" even more marginal as government money for dual use work poured into the field and criticswithin the scientific community have fallen silent. In turn, his denunciationshave grown more sweeping.

In the 1990 book "Preventing a Biological Arms Race," scholar Susan Wright argued that current laws regarding bioweapons were insufficient, as there were "projects in which offensive and defensive aspects can be distinguished only by claimed motive." Boyle notes, correctly, that current law he drafted does not makean exception for "defensive" work, but only for "prophylactic, protective or other peaceful purposes."

While Boyle is particularly vociferous in his condemnations, he is not alone. There has been irregular, but occasional media attention to this threat. The Guardian ran a piece in 2014,"Scientists condemn 'crazy, dangerous' creation of deadly airborne flu virus," afterKawaoka created a life-threatening virus that "closely resembles the 1918 Spanish flu strain that killed an estimated 50m people":

"The work they are doing is absolutely crazy. The whole thing is exceedingly dangerous," said Lord May, the former president of the Royal Society and one time chief science adviser to the UK government. "Yes, there is a danger, but it's not arising from the viruses out there in the animals, it's arising from the labs of grossly ambitious people."

Boyle'scharges beginning early this yearthat the coronavirus was bioengineered allegationsrecently mirrored by French virologist andNobel laureate Luc Montagnier have not been corroborated by any publicly produced findings of any U.S. scientist. Boyle even charges that scientists like Ebright, who is at Rutgers, arecompromised because the university got abiosafety level 3 lab in 2017though Ebright is perhaps the most vocal eminent critic of this research, among U.S. scientists. These and other controversies aside, Boyle's concerns about the dangers of biowarfare arelegitimate; indeed, Ebright shares them.

Some of the most vocal voices to discuss the origins of the novel coronavirushave been eager to minimizethe dangers of lab work, or have focused almost exclusively on "wet markets" or "exotic" animals as the likely cause.

The media celebrated Laurie Garrett, the Pulitzer Prizewinning author and former senior fellow at the Council on Foreign Relations, when she declared on Twitter on March 3 (in a since-deleted tweet)that the origin of the pandemic was discovered: "It's pangolins. #COVID19 Researchers studied lung tissue from 12 of the scaled mammals that were illegally trafficked in Asia and found #SARSCoV2 in 3. The animals were found in Guangxi, China. Another virus+ smuggled sample found in Guangzhou."

She was swiftly corrected by Ebright: "Arrant nonsense. Did you even read the paper? Reported pangolin coronavirus is not SARS-CoV-2 and is not even particularly close to SARS-CoV-2. Bat coronavirus RaTG13 is much closer to SARS-CoV-2 (96.2% identical) than reported pangolin coronavirus (92.4% identical)." He added: "No reason to invoke pangolin as intermediate. When A is much closer than B to C, in the absence of additional data, there is no rational basis to favor pathway A>B>C over pathway A>C." When someone asked what Garrett was saying, Ebright responded: "She is saying she is scientifically illiterate."

The following day, Garrett corrected herself (without acknowledging Ebright): "I blew it on the #Pangolins paper, & then took a few hours break from Twitter. It did NOT prove the species = source of #SARSCoV2. There's a torrent of critique now, deservedly denouncing me & my posting. A lot of the critique is super-informative so leaving it all up 4 while."

At leastone Chinese governmentofficialhas respondedto the allegation that the labs in Wuhan could be the source for the pandemic by alleging that perhaps the U.S. isresponsibleinstead. In American mainstreammedia, that has been reflexivelytreated as evenmore ridiculousthan the original allegation that the virus could havecome froma lab.

Obviouslythe Chinese government'sallegations should not be taken at face value, but neither should U.S. government claims especially considering that U.S. government labs were the apparent source for theanthrax attacks in 2001. Those attacks sent panic through the U.S. and shut down Congress, allowing the Bushadministration to enact the PATRIOT Act and ramp up the invasions of Afghanistan and Iraq. Indeed, in October2001, media darlings like Richard Butler and Andrew Sullivan propagandizedfor war with Iraq because of the anthrax attacks. (Neither Iraq nor al-Qaida was involved.)

The 2001 anthrax attacks also provided muchof the pretext forthe surge in biolab spending since then, even though they apparently originated in a U.S. or U.S.-allied lab. Indeed, thoseattacks remain shrouded in mystery.

The U.S. government has also
come up withelaborate cover stories to distract from its bioweapons work. For instance, the U.S. government infamously claimed the 1953 death of Frank Olson, a scientist at Fort Detrick, Maryland, was anLSD experiment gone wrong;it now appears to have been an execution to cover up for U.S.biological warfare.

Regardless of the cause of the current pandemic, these biowarfare/biodefense labs need far more scrutiny. The call to shut them down by Boyle and others needs to be clearly heard and light must be shone on precisely what research is being conducted.

The secrecy of these labs may prevent us ever knowing with certainty the origins of the current pandemic.What we do know is this kind of lab work comes with real dangers. One might make a comparison to climate change: We cannot attribute an individual hurricane to man-made climate disruption,yet science tells us that human activity makes stronger hurricanes more likely. Thatbrings us back to the imperative to cease the kinds of activities thatproduce such dangers in the first place.

If that doesn't happen, the people of the planet will be at the mercy of the machinations and mistakes of state actors who are playing with fire for their geopolitical interests.

Continue reading here:
Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race - Salon

Scientists from Russia and China have been creating ‘genetic pathogens’ for years | London Business News – London Loves Business

Questions have been asked over China in recent days over how the coronavirus was made and transmitted from animal to human.

The US and the UK have both started investigations into China, with President Donald Trump questioning whether it was a mistake that got out of control or was it started deliberately.

Russia has taken advantage of the situation and had excess supplies of 60 tonnes of medical supplies which were sent to the US.

The Russian state of defence giant Rostec delivered ventilators, via the Kremlin to New York two weeks ago, despite Russia having severe health implications across the country.

The US President Donald Trump said, this is a very nice gesture and he is not worried about Russian propaganda, not even a little bit.

During the 70s the former Soviet Union (FSU) were creating genetic engineering for the next generation of Biological weapons as were the Chinese.

The FSU were accused of making a clandestine and illegal offensive biological weapons program. The Soviet Bioweapons (BW) research and development program also sought out the most contagious and lethal bacteria such as plague, and viruses like smallpox.

Biopreparat was a huge military program with civilian cover, which was organised to develop and weaponise biological agents for BW.

Biopreparat and other Soviet BW research facilities operated under the highest security classification of Special Importance which is higher than Top Secret.

The US intelligence community did not even know it existed until 1989 when a top-ranking scientist from the BW program defected to the UK.

In October 1989, Dr Vladimir Pasechnik, the first primary source from inside the Soviet program, defected to the UK.

Pasechnik disclosed that the Soviets had genetically engineered bacteria and viruses, weaponised the microbes in a powder form, loaded them onto various munitions, and integrated BW into their doctrine and had specific plans for use of BW.

In the spring of 1992, a lower-level bench scientist who had worked on plague research in Pasechniks lab also defected to the UK, he has remained undercover and is referred to by code name Temple Fortune.

He fully corroborated Pasechniks previous account and informed the British government on Russias genetic engineering.

A decade later, after becoming President of Russia, Boris Yeltsen visited Britain in 1992. In a public speech, discussing biological warfare research.

Yeltsin stated that the Russians had undertaken research on the influence of various substances on human genes.

The revolution in molecular biology may have incidentally unleashed a new threat to mankind, the development of deadly bioweapons.

The Centers for Disease Control and Prevention (CDC) in Atlanta, is the lead agency for disease epidemics and tracks naturally occurring emerging infectious diseases worldwide.

The CDC have travelled all over the world and investigated outbreaks of Ebola hemorrhagic fever, Marburg virus, hantavirus, and other emerging diseases, more recently coronavirus.

The US Office of the Secretary of Defense have identified countries that maintain various levels of offensive biological warfare capabilities or research facilities, this includes Russia and China.

Both Russia and China have been genetically engineering pathogens for Biological warfare for decades.

A pathogen may be released clandestinely so there will be a delay between exposure and onset of symptoms, such as coronavirus.

Days to weeks later, when people do develop symptoms, they could immediately start spreading contagious diseases, as the world has witnessed since January 2020 with Covid-19.

A paper, released in 2002 entitled, Next Generation Bioweapons for the USAF Counterproliferation Center which provided information and analysis to assist the understanding of bioweapons.

Colonel Dr Michael Ainscough, USAF and a diplomat of American Board of Preventive Medicine in Aerospace Medicine, said in the paper that entire viruses may similarly be created, analogous to the natural mutation of the influenza virus.

A new strain of influenza could be created by induced hybridisation of viral strains, simply swapping out variant or synthetic genes.

Slightly altering a common virus like influenza to make it deadlier might be easier than manipulating rarer or other biologically complicated pathogens.

Some animal viruses, such as those found in bats, are so small that their entire genome could be stitched together, to from machine-synthesised fragments using current technology.

Adding, Mycoplasma, an organism that causes pneumonia in humans, has the smallest known bacterial genome.

An existing pathogen would be subtly genetically modified to be more difficult to detect, more virulent, or more resistant to drugs, all within the capabilities of todays biotechnology, according to the paper.

China has also been developing such Mycoplasma bacterial genomes, and both Russia and China have been closely working with each other for decades.

The Chinese Army has a role at the Wuhan Institute for Biological Products and at the Wuhan Centre for Disease Control & Prevention.

The report by South Chinas university revealed the theory of the origin of coronavirus.

Surgery was performed on the caged animals and the tissue samples were collected for DNA and RNA extraction and sequencing.

They were only 280metresfrom the seafood market and the WHCDC was also adjacent to the Union Hospital where the first group of doctors were infected during this epidemic.

It is plausible that the virus leaked around and some of them contaminated the initial patients in this epidemic, though solid proof is needed in future studies.

Conservative MP, Tobias Elwood the chairman of the British Defence Select Committee expressed concerns in Febraury over the Chinese Armys role at the Wuhan Institute for Biological Products and called, for the greater transparency over the origins of the coronavirus.

See original here:
Scientists from Russia and China have been creating 'genetic pathogens' for years | London Business News - London Loves Business

The Proto-Communist Plan to Resurrect Everyone Who Ever Lived – VICE

Is there anything that can be done to escape the death cult we seem trapped in?

One of the more radical visions for how to organize human society begins with a simple goal: lets resurrect everyone who has ever lived. Nikolai Fedorov, a nineteenth-century librarian and Russian Orthodoxy philosopher, went so far as to call this project the common task of humanity, calling for the living to be rejuvenated, the dead to be resurrected, and space to be colonized specifically to house them. From the 1860s to the 1930s, Fedorovs influence was present throughout the culturehe influenced a generation of Marxists ahead of the Russian Revolution, as well as literary writers like Leo Tolstoy and Fyodor Dostoevsky, whose novel, The Brothers Karamazov, directly engaged with Federov's ideas about resurrection.

After his death, Federovs acolytes consolidated his ideas into a single text, A Philosophy of the Common Task, and created Cosmism, the movement based on his anti-death eschatology. Federov left the technical details to those who would someday create the prerequisite technology, but this did not stop his disciples: Alexander Bogdanov, who founded the Bolsheviks with Lenin, was an early pioneer of blood transfusions in hopes of rejuvenating humanity; Konstantin Tsiolkvosky, an astrophysicist who was the progenitor of Russia's space program, sought to colonize space to house the resurrected dead; and Alexander Chizhevsky, a biophysicist who sought to map out the effects of solar activity on Earth life and behavior, thought his research might help design the ideal society for the dead to return to.

The vast majority of cosmists were, by the 1930s, either murdered or purged by Stalin, muting the influence of their ambitious project but also leaving us with an incomplete body of work about what type of society resurrection requires or will result in, and whether that wouldas some cosmists believe nowbring us closer to the liberation of the species. Now, I think it is obvious thatdespite what todays transhumanists might tell youwe are in no position, now or anytime soon, to resurrect anyone let alone bring back to life the untold billions that have existed across human history and past it into the eons before civilizations dawn.

To be clear, I think cosmism is absolute madness, but I also find it fascinating. With an introduction to Cosmism and its implications, maybe we can further explore the arbitrary and calculated parts of our social and political order that prioritize capital instead of humanity, often for sinister ends.

**

What? Who gets resurrected? And how?

At its core, the Common Task calls for the subordination of all social relations, productive forces, and civilization itself to the single-minded goal of achieving immortality for the living and resurrection for the dead. Cosmists see this as a necessarily universal project for either everyone or no one at all. That constraint means that their fundamental overhaul of society must go a step further in securing a place where evil or ill-intentioned people cant hurt anyone, but also where immortality is freely accessible for everyone.

Its hard to imagine how that worldwhere resources are pooled together for this project, where humans cannot hurt one another, and where immortality is freeis compatible with the accumulation and exploitation that sit at the heart of capitalism. The crisis heightened by coronavirus should make painfully clear to us all that, as J.W. Masonan economist at CUNYrecently put it, we have a system organized around the threat of withholding people's subsistence, and it "will deeply resist measures to guarantee it, even when the particular circumstances make that necessary for the survival of the system itself." Universal immortality, already an optimistic vision, simply cannot happen in a system that relies on perpetual commodification.

Take one small front of the original cosmist project: blood transfusions. In the 1920s, after being pushed out of the Bolshevik party, Bogdanov focused on experimenting with blood transfusions to create a rejuvenation process for humans (theres little evidence they do this). He tried and failed to set up blood banks across the Soviet Union for the universal rejuvenation of the public, dying from complications of a transfusion himself. Today, young blood is offered for transfusion by industrious start-ups, largely to wealthy and eccentric clientsmost notably (and allegedly) Peter Thiel.

In a book of conversations on cosmism published in 2017 titled Art Without Death, the first dialogue between Anton Vidokle and Hito Steyerl, living artists and writers in Berlin, drives home this same point. Vidokle tells Steyerl that he believes Death is capital quite literally, because everything we accumulatefood, energy, raw material, etc.these are all products of death. For him, it is no surprise were in a capitalist death cult given that he sees value as created through perpetual acts of extraction or exhaustion.

Steyerl echoes these concerns in the conversation, comparing the resurrected dead to artificial general intelligences (AGIs), which oligarch billionaires warn pose an existential threat to humanity. Both groups anticipate fundamental reorganizations of human society, but capitalists diverge sharply from cosmists in that their reorganization necessitates more extraction, more exhaustion, and more death. In their conversation, Steyerl tells Vidokle:

Within the AGI Debate, several solutions have been suggested: first to program the AGI so it will not harm humans, or, on the alt-right/fascist end of the spectrum, to just accelerate extreme capitalisms tendency to exterminate humans and resurrect rich people as some sort of high-net-worth robot race.

These eugenicist ideas are already being implemented: cryogenics and blood transfusions for the rich get the headlines, but the breakdown of healthcare in particularand sustenance in generalfor poor people is literally shortening the lives of millions ... In the present reactionary backlash, oligarchic and neoreactionary eugenics are in full swing, with few attempts being made to contain or limit the impact on the living. The consequences of this are clear: the focus needs to be on the living first and foremost. Because if we dont sort out societycreate noncapitalist abundance and so forththe dead cannot be resurrected safely (or, by extension, AGI cannot be implemented without exterminating humankind or only preserving its most privileged parts).

One of the major problems of todays transhumanist movement is that we are currently unable to equally distribute even basic life-extension technology such as nutrition, medicine, and medical care. At least initially, transhumanists vision of a world in which people live forever is one in which the rich live forever, using the wealth theyve built by extracting value from the poor. Todays transhumanism exists largely within a capitalist framework, and the countrys foremost transhumanist, Zoltan Istvan, a Libertarian candidate for president, is currently campaigning on a platform that shutdown orders intended to preserve human life during the coronavirus pandemic are overblown and are causing irrevocable damage to the capitalist economy (Istvan has in the past written extensively for Motherboard, and has also in the past advocated for the abolition of money).

Cosmists were clear in explaining what resurrection would look like in their idealized version of society, even though they were thin on what the technological details would be. Some argue we must not only restructure our civilization, but our bodies so that we can acquire regenerative abilities, alter our metabolic activity so food or shelter are optional, and thus overcome the natural, social, sexual, and other limitations of the species as Arseny Zhilyaev puts it in a later conversation within the book.

Zhilyaev also invokes Federovs conception of a universal museum, a radicalized, expanded, and more inclusive version of the museums we have now as t
he site of resurrection. In our world, the closest example of this universal museum is the digital world which also doubles as an enormous data collector used for anything from commerce to government surveillance. The prospect of being resurrected because of government/corporate surveillance records or Mormon genealogy databases is sinister at best, but Zhilyaevs argumentand the larger one advanced by other cosmistsis that our world is already full of and defined by absurd and oppressive institutions that are hostile to our collective interests, yet still manage to thrive. The options for our digital worlds development have been defined by advertisers, state authorities, telecom companies, deep-pocketed investors, and the likewhat might it look like if we decided to focus instead on literally any other task?

All this brings us to the question of where the immortal and resurrected would go. The answer, for cosmists, is space. In the cosmist vision, space colonization must happen so that we can properly honor our ethical responsibility to take care of the resurrected by housing them on museum planets. If the universal museum looks like a digital world emancipated from the demands of capital returns, then the museum planet is a space saved from the whims of our knock-off Willy Wonkasthe Elon Musks and Jeff Bezos of the world. I am not saying it is a good or fair idea to segregate resurrected dead people to museum planets in space, but this is what cosmists suggested, and its a quainter, more peaceful vision for space than what todays capitalists believe we should do.

For Musk, Mars and other future worlds will become colonies that require space mortgages, are used for resource extraction, or, in some cases, be used as landing spots for the rich once we have completely destroyed the Earth. Bezos, the worlds richest man, says we will have "gigantic chip factories in space where heavy industry is kept off-planet. Beyond Earth, Bezos anticipates humanity will be contained to O'Neill cylinder space colonies. One might stop and consider the fact that while the cosmist vision calls for improving human civilization on Earth before resurrecting the dead and colonizing space, the capitalist vision sees space as the next frontier to colonize and extract stupendous returns fromtrillions of dollars of resource extraction is the goal. Even in space, they cannot imagine humanity without the same growth that demands the sort of material extraction and environmental degradation already despoiling the world. Better to export it to another place (another country, planet, etc.) than fix the underlying system.

Why?

Ostensibly, the why behind cosmism is a belief that we have an ethical responsibility to resurrect the dead, much like we have one to care for the sick or infirm. At a deeper level, however, cosmists not only see noncapitalist abundance as a virtue in of itself, but believe the process of realizing it would offer chances to challenge deep-seated assumptions about humanity that might aid political and cultural forms hostile to the better future cosmists seek.

Vidokle tells Steyerl in their conversation that he sees the path towards resurrection involving expanding the rights of the dead in ways that undermine certain political and cultural forms,

The dead ... dont have any rights in our society: they dont communicate, consume, or vote and so they are not political subjects. Their remains are removed further and further from the cities, where most of the living reside. Culturally, the dead are now largely pathetical comical figures: zombies in movies, he said. Financial capitalism does not care about the dead because they do not produce or consume. Fascism only uses them as a mythical proof of sacrifice. Communism is also indifferent to the dead because only the generation that achieves communism will benefit from it; everyone who died on the way gets nothing.

In another part of their conversation, Steyerl suggests that failing to pursue the cosmist project might cede ground to the right-wing accelerationism already killing millions:

There is another aspect to this: the maintenance and reproduction of life is of course a very gendered technologyand control of this is on a social battleground. Reactionaries try to grab control over lifes production and reproduction by any means: religious, economic, legal, and scientific. This affects womens rights on the one hand, and, on the other, it spawns fantasies of reproduction wrested from female control: in labs, via genetic engineering, etc.

In other words, the failure to imagine and pursue some alternative to this oligarchic project has real-world consequences that not only kill human beings, but undermine the collective agency of the majority of humanity. In order for this narrow minority to rejuvenate and resurrect themselves in a way that preserves their own privilege and power, they will have to sharply curtail the rights and agency of almost every other human being in every other sphere of society.

Elena Shaposhnikova, another artist who appears later in the book, wonders whether the end of deathor the arrival of a project promising to abolish itmight help us better imagine and pursue lives beyond capitalism:

It seems to me that most of us tend to sublimate our current life conditions and all its problems, tragedies, and inequalities, and project this into future scenarios, she said. So while its easy to imagine and represent life in a society without money and with intergalactic travel, the plot invariably defaults to essentialist conflicts of power, heroism, betrayal, revenge, or something along these lines.

In a conversation with Shaposhnikova, Zhilyaev offers that cosmism might help fight the general fear of socialism as he understands it:

According to Marx, or even Lenin, socialism as a goal is associated with something elsewith opportunities of unlimited plurality and playful creativity, wider than those offered by capitalism. ... the universal museum producing eternal life and resurrection for all as the last necessary step for establishing social justice.

In the conversations that this book, cosmism emerges not simply as an ambition to resurrect the dead but to create, for the first time in human history, a civilization committed to egalitarianism and justice. So committed, in fact, that no part of the human experienceincluding deathwould escape the frenzied wake of our restructuring.

Its a nice thought, and something worth thinking about. Ours is not that world but in fact, one that is committed, above all else, to capital accumulation. There will be no resurrection for the deadthere isnt even healthcare for most of the living, after all. Even in the Citadel of Capital, the heart of the World Empire, the belly of the beast, the richest country in human history, most are expected to fend for themselves as massive wealth transfers drain the public treasuries that mightve funded some measure of protection from the pandemic, the economic meltdown, and every disaster lurking just out of sight. And yet, for all our plumage, our death cult still holds true to Adam Smith's observation in The Wealth of Nations: "All for ourselves, and nothing for other people, seems, in every age of the world, to have been the vile maxim of the masters of mankind."

See more here:
The Proto-Communist Plan to Resurrect Everyone Who Ever Lived - VICE

Biotech and Pharmaceutical Stocks Beat the Market in Recessions – Barron’s

Text size

Looking for a safe harbor during the Covid-19 pandemic? The biotech and pharmaceutical industries deserve a close look, according to SVB Leerink analyst Geoffrey Porges.

The indexes that track the biotech and pharmaceutical sectors outperformed the market in the 2001, 2008-09, and current recessions, he wrote in a Friday morning note.

On average, the biotechnology Indexes declined -1% during the three economic downturns, compared with the pharmaceutical indexs -10% and the S&P 500 indexs -20%. On a relative basis, biotech and pharmaceutical Indices outperformed the S&P 500 by 18% and 10%, respectively, Porges noted.

One likely explanation: People need their medicine, even in a recession. Porges cited published papers showing that pharmaceutical sales volume stayed steady in the U.S. during the 2008-09 recession.

So far this year, biotech indexes and exchange-traded funds have vastly outperformed the market. While the S&P 500 is down 13.4% since the start of the year, the iShares Nasdaq Biotechnology ETF (ticker: IBB) is up 2.2%. The SPDR S&P Biotechnology ETF (XBI) is down 1.4%, while the Nasdaq Biotechnology Index (NBI) is up 2.3%.

Pharmaceutical indexes have also performed well. The NYSE Arca Pharmaceutical index is down 1.1%, while the S&P 500 Pharmaceuticals index is down 0.5%.

Those performances have been boosted by strong showings from large-cap biotech companies like Gilead Sciences (GILD), which is up 19.7% so far this year on excitement over its experimental Covid-19 therapy remdesivir, and Moderna (MRNA), which is up a startling 142.5% so far this year over its Covid-19 vaccine, which is in clinical trials.

Major pharmaceutical companies have also outperformed. Johnson & Johnson (JNJ) is up 6.6%, while Eli Lilly (LLY) is up 21.7%. The company clocked a new 52-week high on Friday morning.

Porges note suggests that all this tracks with the recent history of recessions.

Our analysis of historical recessions suggested that the biotech and pharma indices (and stocks) significantly outperformed the broad market (S&P 500), despite the greater P/E multiple compressions in the healthcare indices, he wrote.

The iShares Nasdaq Biotechnology ETF was up 0.6% in recent trading, while the S&P 500 was up 0.4%.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Link:
Biotech and Pharmaceutical Stocks Beat the Market in Recessions - Barron's

Bayer, Novartis, and Trump convicted by Nature – European Biotechnology

The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.

In the prestigous paper Nature Medicine, cardiologists under Lior Jankelson report that patients with COVID-19 who were on a regimen of Novartis AGs generic malaria drug hydroxychloroquine and the antibiotic azithromycin experienced electrocardiogram abnormalities. Previous reports demonstrated that the same is true for chloroquine phosphate, an old malaria drug originally developed at Bayer AG. The authorsassessed 84 patients with COVID-19 treated at a centre in New York, USA.

Azithromycin in combination with antimalarial hydroxychloroquine has been touted by President Donald Trump as a possible "game changer" in COVID-19. Former BARDA head Rick Bright was fired because he resisted political interventions to push the use of chloroquine derivatives to treat COVID-19 despite scientific evidence of efficacy and safety according to current authorisation standards. Biocentury reported previously that Trumps preference for the cheap but antiquated malaria treatments looked more like political science than actually based on scientific evidence. Several clinical programmes coordinated by the WHO , the European Union, and the UK promote clinical testing of combinations with either chloroquine phosphate or hydroxychloroquine and may cause thousands of deaths unless they were not updated to include new findings.

Several reports demonstrated that both medications increase the risk of various types of cardiac rhythm abnormalities, such as QTc-interval prolongation and drug-inducedtorsades de pointes, and sudden cardiac death. The QTc interval is measured by an electrocardiogram and represents the time it takes for a heart to recharge between beats. A prolonged QTc interval puts a patient at risk for arrhythmia and sudden cardiac death.

Now, Jankelson and colleagues reviewed the charts and followed the QTc interval of 84 patients with COVID-19 on a 5-day oral regiment of hydroxychloroquine and azithromycin. The patients were, on average, 63 years of age and74% were male. After the patients were administered the drugs, the authors followed up with an electrocardiogram. They observed a prolonged QTc in most patients. The QTc was severely prolonged in 11% of the patients, which put them at high risk of arrhythmia and sudden cardiac death. Four patients in the cohort died from multiple organ failure a characteristic of septic shock without evidence of arrhythmia and without severe QTc prolongation.

Jankelson and colleagues found that most patients with COVID-19 who were treated with hydroxychloroquine and azithromycin experienced QTc prolongation. This may have been exacerbated by other pre-existing conditions and the severity of the SARS-CoV-2 infection. The authors conclude that the QTc in patients with COVID-19 who are treated with hydroxychloroquine and azithromycin should be monitored constantly, especially for patients with additional illnesses and those who are being treated with other QT-prolonging medications.

See the rest here:
Bayer, Novartis, and Trump convicted by Nature - European Biotechnology

Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

A rating of 18 puts SAGE Therapeutics Inc (SAGE) near the bottom of the Biotechnology industry according to InvestorsObserver. SAGE Therapeutics Inc's score of 18 means it scores higher than 18% of stocks in the industry. SAGE Therapeutics Inc also received an overall rating of 35, putting it above 35% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

SAGE Therapeutics Inc (SAGE) stock is trading at $38.00 as of 1:22 PM on Friday, Apr 24, a rise of $1.76, or 4.86% from the previous closing price of $36.24. The stock has traded between $35.62 and $38.03 so far today. Volume today is light. So far 545,172 shares have traded compared to average volume of 1,562,765 shares.

To see InvestorsObserver's Sentiment Score for SAGE Therapeutics Inc click here.

Go here to see the original:
Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? – InvestorsObserver

Mesoblast limited (MESO) is near the top in its industry group according to InvestorsObserver. MESO gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Mesoblast limited gets a 95 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mesoblast limited (MESO) stock is trading at $16.61 as of 10:30 AM on Friday, Apr 24, an increase of $10.16, or 157.52% from the previous closing price of $6.45. The stock has traded between $14.33 and $20.57 so far today. Volume today is above average. So far 12,327,011 shares have traded compared to average volume of 428,508 shares.

To screen for more stocks like MESO click here.

Read more here:
Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Why biotech’s goal should not be to feed the world – SynBioBeta

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read more from the original source:
Why biotech's goal should not be to feed the world - SynBioBeta

Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors – Yahoo Finance

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Companys Board of Directors.

"Julie is an accomplished biotechnology executive who brings extensive oncology clinical drug development expertise to our Board of Directors," said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. "As we continue to advance AO-176 in clinical development for select solid tumors and plan for additional indications in hematologic malignancies including multiple myeloma, I am thrilled to have Julie join the Board of Directors. We share a deep commitment to developing novel therapies for patients with cancer and I look forward to working with her."

Julie Hambleton, M.D., Chief Medical Officer at IDEAYA Biosciences and Director for Arch Oncology, added, "I am very encouraged by the growing body of preclinical data, the clinical progress, and future clinical potential of AO-176. This novel anti-CD47 antibody has a best-in-class profile and I look forward to sharing my insights gained over 20 years in drug development to guide ongoing and future potential opportunities for AO-176 in across various oncology indications."

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton serves as Chief Medical Officer of IDEAYA Biosciences. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director,Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

In addition, Dr. Hambleton serves as a Director on IGM Biosciences Board of Directors.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with select solid tumors and hematologic malignancies, including multiple myeloma. The Companys next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncologys lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of antibody pipeline programs for the treatment cancer. For more information please visit http://www.archoncology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005212/en/

Contacts

Amy Figueroa, CFAFor Arch Oncologyafigueroa@archoncology.com 650-823-2704

Continued here:
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors - Yahoo Finance

Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) – US Post News

The recent performance of Vir Biotechnology (NASDAQ:VIR) stock in the market spoke loud and clear to investors as VIR saw more than 1.13M shares in trading volumes in the last trading session, way higher than the average trading volume of 1.13M shares by far recorded in the movement of Vir Biotechnology (VIR). At the time the stock opened at the value of $29.55, making it a high for the given period, the value of the stock jumped by 3.56%. After the increase, VIR touched a low price of $29.55, calling it a day with a closing price of $30.08, which means that the price of VIR went 1.6 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of VIR stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $34.33 for VIR within consensus. The estimated price would demand a set of gains in total of -37.91%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 100.45M in the public float and 3.41B US dollars in market capitalization.

When it comes to the technical analysis of VIR stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, VIR stock are showing 26.08% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, VIR with the present state of 200 MA appear to be indicating bullish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of VIR, the general sentiment in the market is inclined toward positive trends.

With the previous 100-day trading volume average of 543315 shares, Pinnacle Financial Partners (PNFP) recorded a trading volume of 717220 shares, as the stock started the trading session at the value of $34.35, in the end touching the price of $34.88 after jumping by 1.54%.

PNFP stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 25.47%.Then price of PNFP also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of PNFP stock during the period of the last months recorded 6.96%, whilst it changed for the week, now showing 5.92% of volatility in the last seven days. The trading distance for this period is set at -7.95% and is presently away from its moving average by -22.96% in the last 50 days. During the period of the last 5 days, PNFP stock lost around -2.84% of its value, now recording a dip by -37.07% reaching an average $55.32 in the period of the last 200 days.During the period of the last 12 months, Pinnacle Financial Partners (PNFP) dropped by -45.50%.

According to the Barcharts scale, the companys consensus rating was unchanged to 4.00 from 4.00, showing an overall improvement during the course of a single month. Based on the latest results, analysts are suggesting that the target price for PNFP stock should be $34.88 per share in the course of the next 12 months. To achieve the target price as suggested by analysts, PNFP should have a spike by 0% in oppose to its present value in the market. Additionally, the current price showcases a discount of 34.19% when compared to the high consensus price target predicted by analysts.

PNFP shares recorded a trading volume of 588569 shares, compared to the volume of 638.57K shares before the last close, presented as its trading average. With the approaching 5.92% during the last seven days, the volatility of PNFP stock remained at 6.96%. During the last trading session, the lost value that PNFP stock recorded was set at the price of $34.88, while the lowest value in the last 52 weeks was set at $27.80. The recovery of the stock in the market has notably added 25.47% of gains since its low value, also recording -0.11% in the period of the last 1 month.

Read the original post:
Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) - US Post News

Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr – News.MarketSizeForecasters.com

The ' Biotechnology Separation Systems market' research report is latest addition by Market Study Report, LLC, that elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Biotechnology Separation Systems market.

The latest report on the Biotechnology Separation Systems market is a depiction of the end-to-end analysis of this business vertical, and includes quite some information about the industry, with respect to pivotal parameters such as the most recent market tendencies, present revenue, market share, market size, periodic deliverables, and profits estimations for the forecast period.

Request a sample Report of Biotechnology Separation Systems Market at:https://www.marketstudyreport.com/request-a-sample/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A brief overview of how the Biotechnology Separation Systems market will perform over the projected timeframe has been given in the report. Also, details about the driving aspects influencing the market dynamics as well as the growth rate that the industry is expected to register over the forecast duration have been delivered. Additionally, the Biotechnology Separation Systems market report also delivers a brief of the challenges that this vertical is defined by, in conjunction with the growth opportunities that this business space is remnant of.

Main pointers highlighted in the Biotechnology Separation Systems market report:

Unveiling the Biotechnology Separation Systems market with regards to the regional terrain:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

A gist of the details presented in the market report with regards to the major industry indicators:

Ask for Discount on Biotechnology Separation Systems Market Report at:https://www.marketstudyreport.com/check-for-discount/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A comprehensive gist of the Biotechnology Separation Systems market with regards to the product and application spectrums:

Product landscape:

Product types: Membrane Filtration, Liquid Chromatography, Centrifuge, Electrophoresis, Flow Cytometry and Others

Key insights presented in the report:

Application landscape:

Application segmentation: Commercial and Scientific Research

Specifics provided in the report:

Other major pointers included in the report:

Some details about the competitive terrain of the Biotechnology Separation Systems market include:

Vendor base of the industry: Danaher, Sartorius Stedim Biotech, Thermo Fisher Scientific, Merck, GE Healthcare, BD, Alfa Wassermann, Agilent, Shimadzu, Sysmex, Bio-Rad Laboratories, PerkinElmer, Alfa Laval, Illumina, 3M Purification, Novasep, Hitachi Koki, Affymetrix, Waters and Repligen

Competitive analysis parameters enlisted in the report include:

The Biotechnology Separation Systems market evaluation exhibits substantial details about the aspects like market concentration ratio.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-biotechnology-separation-systems-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Biotechnology Separation Systems Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

2. Global Low-Earth Orbit Satellite Market Growth 2020-2025Low-Earth Orbit Satellite Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-low-earth-orbit-satellite-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/military-laser-systems-market-analysis-with-key-players-applications-trends-and-forecast-to-2025-2020-04-24

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email:

See the original post:
Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr - News.MarketSizeForecasters.com

Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 3.56% from its latest closing price when compared to the 1-year high value of $75.00 and move down -140.77%, while VIR stocks collected +6.21% of gains with the last five trading sessions. Press Release reported on 04/15/20 that VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

VIR stocks went up by 6.21% for the week, with the monthly drop of -4.89% and a quarterly performance of 83.45%. The simple moving average for the period of the last 20 days is 0.29% for VIR stocks with the simple moving average of 44.30% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -58.47% of loss for the given period.

The stock volatility was left at 11.09%, however, within the period of a single month, the volatility rate increased by 7.37%, while the shares surge at the distance of +1.30% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +70.78% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +6.21%. In addition, Vir Biotechnology, Inc. saw 147.71% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

See original here:
Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? - The News Heater

Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months – The InvestChronicle

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.15 to be very precise. The Stock rose vividly during the last session to $31.4 after opening rate of $29.55 while the lowest price it went was recorded $29.55 before closing at $30.08.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.47% during the 52-week period from high price, and 167.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.56 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 147.71%, having the revenues showcasing 83.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.41B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 24.32, with a change in the price was noted +19.25. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +161.76% for the period of last 100 days, recording 780,574 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 25.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.58%. In the last 20 days, the companys Stochastic %K was 27.22% and its Stochastic %D was recorded 25.85%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 147.71%. The shares increased approximately by 1.57% in the 7-day charts and went up by 6.21% in the period of the last 30 days. Common stock shares were driven by 83.45% during last recorded quarter.

Go here to see the original:
Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months - The InvestChronicle